Annual revenue rose from KRW 5.66 trillion in 2022 to KRW 6.03 trillion in 2024 before declining 2.4% to KRW 5.89 trillion in 2025, with 2024 the largest year and 2022 the smallest in the 2022–2025 period.
Operating profit fell 66.9% to KRW 102.9 billion in 2023, turned into an operating loss of KRW 89.6 billion in 2024, and returned to a profit of KRW 60.5 billion in 2025. The operating margin stayed low, at 5.5% in 2022, 1.7% in 2023, -1.5% in 2024 and 1.0% in 2025.
Attributable net profit went from KRW 137.2 billion in 2022 to KRW 8.57 billion in 2023 and KRW 170.3 billion in 2024, then turned into an attributable net loss of KRW 158.5 billion in 2025.
Net profit including non-controlling interests was a loss of KRW 296.6 billion in 2025, which means the non-controlling share also absorbed losses.
In the quarters, Q4 2025 showed an operating loss of KRW 88.8 billion and an attributable net loss of KRW 111.7 billion, and Q1 2026 returned to operating profit of KRW 98.8 billion. Q2 2026 operating profit of KRW 99.8 billion edged up 1.1%, but Q3 2026 fell to KRW 41.4 billion, down 58.5% from the prior quarter.
Q3 revenue rose 20.4% year on year, while reports attributed the profit decline partly to slower new-car sales at the imported-car distribution group.
Attributable net profit of KRW 79 billion in Q3 rose sharply from a year earlier, and reports linked the net profit line to a derivative valuation gain at Kolon TissueGene.
Reports also tied the same kind of valuation swing to a net loss of KRW 44.7 billion in Q1 2026, so quarterly net profit can move independently of operating strength.